ArticleBMC oral health2025
Global, regional and national burden of lip and oral cavity cancer from 1990 to 2021 and projections to 2036.
Article in BMC oral health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Global Epidemiological Insights: Temporal Trends and Disparities in Oral Cavity Cancer Mortality in the United States, 1999-2024.International dental journal · 2026Article
- Lessons From Astaxanthin Therapy to Combat Oral Premalignant and Malignant Lesions: A Narrative Review.Health science reports · 2026Article
- Burden, Trends and Projection of Lip and Oral Cavity Cancer in Central, Eastern and Western Europe: From the Global Burden of Disease 2023 Study.International dental journal · 2026Article
- Evaluating Large Language Models for Diagnostic Accuracy and Health Information Quality in Oral Mucosal Diseases.Journal of personalized medicine · 2026Article
- Overall survival and prognostic factors of oral cavity and oropharyngeal squamous cell carcinomas in Saudi Arabia: a population-based cohort study (2000-2019).Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectiveTo explore the global trends in the incidence, mortality and disability-adjusted life years (DALYs) of lip and oral cavity cancer from 1990 to 2021, analyze regional, age and gender differences in lip and oral cavity cancer across the world, and predict future trends.
methodsThe data were all from the Global Burden of Disease (GBD) database, calculating the global incidence, mortality and DALY rates of lip and oral cavity cancer per 100,000 population. The estimated annual percent change (EAPC) was calculated and a Bayesian age-period-cohort (BAPC) analysis was conducted. The fitting curves of the disease burden indicators and the socio-demographic index (SDI) were analyzed.
resultsGlobally, incident cases of lip and oral cavity cancer in 2021 were 421,577 (95% UI, 389,878.79-449,782.06), number of deaths was 208,379 (95% UI, 191,287.97-224,162.08) and number of DALY was 5,874,070 (95% UI, 5,326,986.06-6,347,557.28). From 1990 to 2021, the incidence increased by 63.68%, the mortality rate increased by 44.6%, and the DALY rate increased by 35.21%. Among the five SDI regions, the incidence, mortality, and DALY rate in middle SDI regions have seen the largest increases, with EAPC of 2.83% (95% CI, 2.69-2.97), 1.99% (95% CI, 1.9-2.07), and 1. 71% (95%CI, 1.64-1.78). From the perspective of 21 regions, the incidence of lip and oral cavity cancer was highest in Australasia in 2021 (11.21 per 100,000; 95%UI, 9.97-12.4). At the national level, Palau has the highest incidence, mortality, and DALY rate globally (32.32 per 100,000; 95%UI, 24.64-41.33, 17.62 per 100,000; 95%UI, 13.37-22.83, 558.99 per 100,000; 95%UI, 420.48-735.74). BAPC forecasts a global rise in age-standardized incidence rate (ASIR) and age-standardized DALY rate (ASDR) for this cancer in the coming years.
conclusionFrom 1990 to 2021, global rates of lip and oral cavity cancer incidence, mortality, and DALY rates increased significantly, with particularly notable rises in low-middle and middle SDI regions. This highlights the urgency of taking targeted intervention measures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.